Skip to content

Chronic kidney disease

Three KDIGO guidelines: CKD evaluation and management (2024), anaemia in CKD (2026), which replaces the 2012 anaemia guideline, and the CKD-MBD update (2017).

KDIGO CKD 2024

International Current

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Official source

KDIGO Anaemia 2026

International Current

KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease

Official source

KDIGO CKD-MBD 2017

International Current

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-Mineral and Bone Disorder

Official source

Clinical pearls

  • CKD = >3 months of abnormal structure or function; classify by Cause, GFR and Albuminuria.
  • Pillars: RASi, SGLT2i (eGFR ≥20, continue below), statin, finerenone (T2D with albuminuria), GLP-1 RA.
  • Anaemia: iron first; ESA target Hb <11.5 g/dL; HIF-PHIs are second line.
  • CKD-MBD: treat trends; restrict calcium binders; dialysis PTH 2–9 × ULN.